Effects of a wake-promoting drug, CX717, on recovery sleep following overnight work

The efficacy of the ampakine CX717 to maintain wakefulness was assessed using recordings of the EEG during recovery sleep following extended wakefulness. 

Spectral analysis of the EEG followed by linear modelling indicated that CX717 modified the EEG, with changes indicative of increased arousal during recovery sleep most evident following the 1000mg dose.

Copyright © 2014 BioSigma Ltd.

BioSigma Ltd is Registered in England - Company No: 7635669   
Registered address: Woodview, Stapley Lane, Ropley, Alresford, Hampshire SO24 0EL